

# AGOMAB

## Agomab to Participate in Upcoming Conferences

**Antwerp, Belgium, May 14, 2026** – [Agomab Therapeutics NV](#) (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:

- **ATS International Conference 2026.** Poster Board #904 titled ‘*AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects*’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
- **H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.** Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
- **2026 RBC Capital Markets Global Healthcare Conference.** Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
- **JPM European Healthcare Symposium.** Wednesday, June 10, 2026 in London, UK.
- **BIO International Convention.** Monday, June 22 - Thursday, June 25, 2026 in San Diego, CA.
- **2026 Leerink Partners Therapeutics Forum.** One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.

### About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

### Contacts

#### Investors

Sofie Van Gijssel

VP of Investor Relations

E-Mail: [sofie.vangijssel@agomab.com](mailto:sofie.vangijssel@agomab.com)

Phone: +1 781 296 1143

#### Media

Gretchen Schweitzer

Trophic Communications

E-Mail: [agomab@trophic.eu](mailto:agomab@trophic.eu)

Phone: +49 172 861 8540